Physician survey results on priorities for screening and treatment for chronic hepatitis C
| Priorities for screening and management | n (%) |
|---|---|
| Which patients need to be screened for HCV infection? (n=91) | |
| A. History of or current injection drug use | 3 (3.3) |
| B. Healthcare workers | 1 (1.1) |
| C. Children born to HCV-infected women | 0 (0) |
| D. Prior recipients of medical procedures, such as transfusions, organ transplants, haemodialysis, surgical procedures | 4 (4.4) |
| E. Patients with unexplained ALT levels | 2 (2.2) |
| F. All patients with A–E | 65 (71.4) |
| G. All older patients | 16 (17.6) |
| Which patients should be prioritised for HCV treatment? (n=81) | |
| A. Patients with advanced fibrosis or cirrhosis (stages 3–4) | 11 (13.6) |
| B. Patients with cirrhosis | 1 (1.2) |
| C. Liver transplant recipients or patients on immunosuppression for other diseases | 1 (1.2) |
| D. Patients with severe extrahepatic hepatitis C | 3 (3.7) |
| E. Patients with HIV coinfection | 2 (2.5) |
| F. Patients with HBV coinfection | 0 (0) |
| G. Patients with other coexistent liver diseases (eg, NASH) | 29 (35.8) |
| H. All patients A–G | 22 (27.2) |
| I. All patients with chronic HCV regardless of severity | 12 (14.8) |
ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis.